Hightide Therapeutics Inc (HK:2511) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HighTide Therapeutics Inc. has successfully completed patient enrollment for its Phase III clinical trial comparing HTD1801 with dapagliflozin for treating Type 2 Diabetes Mellitus. This trial, which involves 358 participants, aims to assess the effectiveness of HTD1801 in improving glucose metabolism and insulin resistance. Final results are anticipated in 2025, marking a significant milestone in the company’s development of innovative therapies for metabolic diseases.
For further insights into HK:2511 stock, check out TipRanks’ Stock Analysis page.